We have discovered a novel series of small molecules that can increase glutamate transporter EAAT2 expression via a novel translational activation mechanism. We have proven that these molecules are capable of providing significant benefits in two mouse models of Alzheimer's disease. We have identified a clinical candidate. The focus of this study is to move this molecule into and through IND enabling studies and be ready to begin Phase I Clinical Studies.